Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model

Microbiology and Immunology

Volumn 57, Issue 11, 2013, Pages 762-771

  Barman, Soumik ^a,d   Koley, Hemanta ^a   Ramamurthy, Thandavarayan ^a   Chakrabarti, Manoj Kumar ^a   Shinoda, Sumio ^b   Nair, Gopinath Balakrish ^c   Takeda, Yoshifumi ^b,e  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^b OKAYAMA UNIVERSITY   (Japan)

^c Translational Health Science and Technology Institute   (India)

^d OSAKA UNIVERSITY   (Japan)

^e Hideyo Noguchi Memorial Foundation   (Japan)

Author keywords

Heat killed Shigella cells; Hexavalent Shigella immunogen; Protective immunity; Shigellosis

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; SHIGELLA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; COLITIS; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL GUINEA PIG; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INTESTINE LAVAGE; MALE; NONHUMAN; SHIGELLA BOYDII; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS;

HEAT-KILLED SHIGELLA CELLS; HEXAVALENT SHIGELLA IMMUNOGEN; PROTECTIVE IMMUNITY; SHIGELLOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; COLITIS; DISEASE MODELS, ANIMAL; DYSENTERY, BACILLARY; FEMALE; GUINEA PIGS; HUMANS; IMMUNIZATION; MALE; SHIGELLA; SHIGELLA VACCINES; VACCINES, INACTIVATED;

EID: 84887764371     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12095     Document Type: Article

References (27)

1. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. (2010) Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 5: 540-53.
2. Phalipon A., Mulard L.A., Sansonetti P.J. (2008) Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path? Microb Infect 10: 1057-62.
3. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., Adak G.K., Levine M.M. (1999) Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. B World Health Organ 77: 651-66.
4. Pazhani G.P., Ramamurthy T., Mitra U., Bhattacharya S.K., Niyogi S.K. (2005) Species diversity and antimicrobial resistance of Shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhoea in Kolkata (Calcutta), India. Epidemiol Infect 133: 1089-95.
5. von Seidlein L., Kim D.R., Ali M., Lee H., Wang X., Thiem V.D., Canh do G., Chaicumpa W., Agtini M.D., Hossain A, Bhutta Z.A., Mason C., Sethabutr O., Talukder K., Nair G.B., Deen J.L., Kotloff K., Clemens J. (2006) A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations and microbiology. PLoS Med 3: e353.
6. Njuguna H.N., Cosmas L., Williamson J., Nyachieo D., Olack B., Ochieng J.B., Wamola N., Oundo J.O., Feikin D.R., Mintz E.D., Breiman R.F. (2013) Use of population-based surveillance to define the high incidence of shigellosis in an urban slum in Nairobi, Kenya. PLoS ONE 8: e58437.
7. Dutta S., Rajendran K., Roy S., Chatterjee A., Dutta P., Nair G.B., Bhattacharya S.K., Yoshida S.I. (2002) Shifting serotypes, plasmid profile analysis and antimicrobial resistance pattern of Shigellae strains isolated from Kolkata, India during 1995- 2000. Epidem Infect 129: 235-43.
8. Nair G.B., Ramamurthy T., Bhattacharya M.K., Krishnan T., Ganguly S., Saha D.R., Rajendran K., Manna B., Ghosh M., Okamoto K., Takeda Y. (2010) Emerging trends in the etiology of enteric pathogens as evidenced from an active surveillance of hospitalized diarrhoeal patients in Kolkata, India. Gut Pahthog 2: 4. doi: 10.1186/1757-47492
9. Ghosh S., Pazhani G.P., Chowdhury G., Guin S., Dutta S., Rajendran K., Bhattacharya M.K., Takeda Y., Niyogi S.K., Nair G.B., Ramamurthy T. (2011) Genetic characteristics and changing antimicrobial resistance among Shigella spp. Isolated from hospitalized diarrhoeal patients in Kolkata, India. J Med Micribiol 60: 1460-6.
10. Niyogi S.K. (2005) Shigellosis. J Microbiol 43: 133-43.
11. Alanis A.J. (2005) Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res 36: 697-705.
12. Steele D., Riddle M., van de Verg L., Bourgeois L. (2012) Vaccines for enteric diseases: a meeting summary. Expert Rev Vaccines 11: 407-9.
13. Kweon M.N. (2008) Shigellosis: the current status of vaccine development. Curr Opin Infect Dis 21: 313-8.
14. Sereny B. (1955) Experimental Shigella keratoconjunctivitis; a preliminary report. Acta Microbiol Acad Sci Hung 2: 293-6.
15. Barman S., Kumar R., Choudhury G., Saha D.R., Wajima T., Hamabata T., Ramamurthy R., Nair G.B., Takeda Y., Koley H. (2011) Live non-invasive Shigella dysenteriae 1 strain induces homologous protective immunity in a guinea pig colitis model. Microbiol Immunol 55: 683-93.
16. Shim D.H., Suzuki T., Chang S.Y., Park S.M., Sansonetti P.J., Sasakawa C., Kweon M.N. (2007) New animal model of shigellosis in the guinea pig: its usefulness for protective efficacy studies. J Immunol 178: 2476-82.
17. Camacho A.I., Irache J.M., Gamazo C. (2013) Recent progress towards development of a Shigella vaccine. Expert Rev Vaccines 12: 43-55.
18. Kaminski R.W., Oaks E.V. (2009) Inactivated and subunit vaccines to prevent shigellosis. Expert Rev Vaccines 8: 1693-704.
19. Osorio M., Bray M.D., Walker R.I. (2007) Vaccine potential for inactivated shigellae. Vaccine 25: 1581-92.
20. Keren D.F., Collins H.H., Gemski P., Holt P.S., Formal S.B. (1981) Role of antigen form in development of mucosal immunoglobulin A response to Shigella flexneri antigens. Infect Immun 31: 1193-202.
21. McKenzie R., Walker R.I., Nabors G.S., Van De Verg L.L., Carpenter C., Gomes G., Forbes E., Tian J.H., Yang H.H., Pace J.L., Jackson W.J., Bourgeois A.L. (2006) Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine 24: 3735-45.
22. Formal S.B., Kent T.H., May H.C., Palmer A., Falkow S., LaBrec E.H. (1966) Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J Bacteriol 92: 17-22.
23. Chakrabarti M.K., Bhattacharya J., Bhattacharya M.K., Nair G.B., Bhattacharya S.K., Mahalanabis D. (1999) Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta Paediatr 88: 161-5.
24. Mukhopadhaya A., Mahalanabis D., Khanam J., Chakrabarti M.K. (2003) Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition. Vaccine 21: 3043-50.
25. Formal S.B., Oaks E.V., Olsen R.E., Wingfield-Eggleston M., Snoyy P.J., Cogan J.P. (1991) Effect of prior infection with Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J Infect Dis 164: 534-7.
26. Noriega F.R., Liao F.M., Maneval D.R., Ren S., Formal S.B., Levine M.M. (1999) Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun 67: 782-8.
27. Neutra M.R., Kozlowski P.A. (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-58.